This is a pilot research study examining the use of varenicline (Chantix) and the nicotine patch. The study is designed to find out whether one of these medications is more effective for smoking cessation with head and neck cancer patients. The study has three parts: 1) two intake sessions; 2) an 8-week treatment phase, and 3) a 3-month follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
7
2 mg
21 mg
Yale University School of Medicine
New Haven, Connecticut, United States
To develop an effect size estimate for smoking cessation defined as continuous abstinence over the last 4 weeks of treatment for 2 mg varenicline compared to nicotine patch.
Time frame: Eight weeks
To examine tolerability of 2 mg varenicline and the 21 mg nicotine patch in smokers who have been diagnosed with head and neck cancer.
Time frame: Eight weeks
To examine the effects of smoking cessation, varenicline and nicotine patch on markers of inflammation.
Time frame: Eight weeks
To examine the effect of varenicline and nicotine patch on alcohol consumption.
Time frame: Eight weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.